RNS Number : 7153O MaxCyte, Inc. 02 February 2023 MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences ROCKVILLE, MD , February 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering
ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative
RNS Number : 2143O MaxCyte, Inc. 30 January 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights ROCKVILLE, MD , January 30, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
RNS Number : 5691L MaxCyte, Inc. 04 January 2023 MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 5209I MaxCyte, Inc. 05 December 2022 MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases Curamys to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to help advance its cell
RNS Number : 5048I MaxCyte, Inc. 02 December 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 2 December 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 2271I MaxCyte, Inc. 01 December 2022 MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD , 1 December, 2022 : MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell - engineering focused company providing enabling platform technologies to
RNS Number : 0603G MaxCyte, Inc. 11 November 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
